# 07 — Additional Bio-Agent Systems & AI for Longevity (2024–2026)

*Companion digest covering additional breakthroughs surfaced via alternative-keyword searches and mapping how agentic biology advances the three stages of defeating aging.*

---

## 1. Key Bio-Agent & Co-Folding Systems Surfaced in Extended Search

| System / Model | Venue / Date | Orgs | Core Contribution & Verified Numbers |
| :--- | :--- | :--- | :--- |
| **BioDiscoveryAgent** | *arXiv:2405.17631* / ICLR | Stanford, Arc (Roohani, Marson, Liang, Leskovec) | Closed-loop LLM agent (`128` genes/round) designing CRISPR perturbation experiments; **`+21–23%` avg hit rate** & **`+46%` on non-essential genes** vs. Bayesian optimization (`~17` extra relevant genes/dataset). |
| **TxAgent (`ToolUniverse`)** | *arXiv* (Mar 2025) | Harvard (Marinka Zitnik Lab) | Multi-step therapeutic reasoning across **`211+` tools** via **`ToolRAG`** (openFDA since 1939, Open Targets, HPO); hits **`~92.1%`** accuracy on open-ended drug/treatment benchmarks (`DrugPC`, etc.), outperforming `GPT-4o` & `DeepSeek-R1`. |
| **Paper2Agent** | *Nature* (Sept 2026) | Stanford (Jiacheng Miao & James Zou) | Multi-agent system converting published papers + code repos into executable **MCP servers** ("virtual corresponding authors"); demonstrated wrapping **AlphaGenome** and **Scanpy / TISSUE**. |
| **CellAgent & scAgents** | *ICLR / ICML* | Academic Consortia | Hierarchical multi-agent scRNA-seq, scATAC-seq, CITE-seq, and spatial workflows (`Planner + Executor + Evaluator` atop `sc-Omni`). |
| **IsoDDE** | Released Feb 2026 (`$2.1B` Series B May '26) | Isomorphic Labs (Alphabet) | Successor to AlphaFold 3 unifying 3D co-folding, ligand docking, affinity estimation, and cryptic pockets; **doubles AF3 success rate** on *Runs N' Poses* out-of-distribution generalization. |
| **Boltz-2 & Chai-2** | Mid-2025 / 2026 | MIT, Recursion, NVIDIA / Chai Discovery | **Boltz-2:** open biomolecular model jointly predicting structure + FEP+-grade binding affinity **up to `1,000x` faster (`~18s` on 1 GPU)**, built to steer GFlowNet agents like `SynFlowNet`. |

---

## 2. AI + Longevity: Mapping the Three Stages of Defeating Aging

Following Anthropic CEO Dario Amodei's *"Machines of Loving Grace"* thesis—that AI acting as virtual scientists can compress `50–100 years` of biology into `5–10 years`, pushing toward a `~150-year` healthspan—recent 2025–2026 breakthroughs map cleanly onto **three escalating biological stages**:

### Stage 1: Conquering Major Killer Diseases (Cancer, Cardiovascular, Fibrosis, Blindness)
* **Heart Disease (*in vivo* Base Editing — `VERVE-102`):** Verve Therapeutics (acquired by Eli Lilly; interim Phase 1 data, *NEJM* mid-2026) showed a **single infusion** permanently silencing hepatic `PCSK9` lowered PCSK9 protein by up to **`88%`** and LDL cholesterol by up to **`62%`** with durability through **18 months**.
* **Cancer & Immunotherapy (`AutoScreen`, `AI Co-Scientist`, `OriGene`, `Virtual Biotech`):** Swarm target triage rescues immune-evasion genes (`MUC1` `#118 -> #5` in NK killing assays), validates repurposed AML candidates (`KIRA6`), nominates `GPR160`/`ARG2` in patient organoids, and quantifies **`+48%` Phase IV approval lift** for cell-type-specific targets.
* **Organ Fibrosis, Blindness & Autophagy:** `AI Co-Scientist` (`Vorinostat` cut TGF$\beta$ liver fibrosis remodeling **`91%`** in `microHO`), FutureHouse `Robin` (`ripasudil` & `KL001` via *ABCA1* in dry AMD RPE cells), and Retro Biosciences' **`RTR242`** autophagy small molecule entering Phase 1.

### Stage 2: Boosting Immunity & Tissue Self-Healing
* **Clearing Senescent ("Zombie") Cells & Inflammaging:** Insilico Medicine launched **"Longevity Vaccines"**—programmable single-shot circular mRNA (`cmRNA-LNP`) cell therapies engineered to selectively eliminate senescent lymphocytes, fibrotic cells, and autoreactive drivers of chronic systemic aging inflammation.
* **Rescuing Aged Tissues & Immune Function (`NewLimit`):** Backed by a **`$435M` Series C (`$3.1B` valuation)**, NewLimit's automated *Ambrosia* AI screening engine discovered LNP-mRNA transcription factor payloads restoring youthful regenerative capacity in aged human **hepatocytes (liver)** alongside preclinical programs for **kidney vascular endothelium** and **aging T cells**.
* **Sys-Wide Frailty & Neuroinflammation Reduction (`ClockBase Agent`):** Validated **`ouabain`** in aged mice, cutting brain microglial neuroinflammation, lifting cardiac output, and slowing frailty progression.

### Stage 3: Rewinding & Verifying the Biological Aging Clock (Partial Epigenetic Reprogramming)
* **Autonomous Aging-Clock Mining (`ClockBase Agent`, Harvard / Gladyshev Lab, *bioRxiv* late 2025):** Reanalyzed decades of non-aging GEO molecular datasets across **`40+` biological aging clocks**, uncovering **`500+` overlooked age-reducing interventions** and proving loss-of-function genetic interventions often outperform gain-of-function perturbations.
* **Multimodal Geroprotector Foundation Models (`Precious-3GPT` & `Longevity-LLM`):** Multi-omics, multi-species transformers outperforming single-modality DNA-methylation Horvath clocks.
* **AI-Engineered Yamanaka Factors Without Losing Cell Identity:**
  * **`GPT-4b micro` (OpenAI + Retro Biosciences):** Redesigned Yamanaka factors (`RetroSOX`, `RetroKLF`) achieving **`>50x` higher stem-cell reprogramming markers** and enhanced DNA damage repair *in vitro*.
  * **`Shift Bioscience` (`SB000`):** Combines virtual cell simulations with epigenetic clocks to pick safe gene combinations that reset cellular age while preserving tissue identity.
  * **`Life Biosciences` (Early 2026 Milestone) & `Altos Labs` (`$3B`):** Life Biosciences received **FDA clearance for the first human clinical trial of partial epigenetic reprogramming** (starting with optic neuropathies), marking the transition of cellular clock reset from computational prediction into human clinical testing.